Chelsea Mashburn, PA
Family Medicine · Mobile, ALNPI 1962944355
Payments from drug & device makers
Across 145 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$598
- Novo Nordisk$369
- Pfizer$295
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$223
- AstraZeneca$178
- Corium, LLC$116
- plus $780 from 18 others
What the payments were for
- Food & beverage$2,558100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $598 |
| Novo Nordisk | 22 | $369 |
| Pfizer | 15 | $295 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $223 |
| AstraZeneca | 8 | $178 |
| Corium, LLC | 7 | $116 |
| Lilly USA, LLC | 7 | $109 |
| GSK | 7 | $108 |
| Exact Sciences | 5 | $88 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Dexcom, Inc. | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Novartis | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
How this compares
$2,558 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $95,140 |
| MounjaroTirzepatide | 46 | $52,771 |
| TrulicityDulaglutide | 16 | $23,772 |
| LinzessLinaclotide | 26 | $23,716 |
| VraylarCariprazine Hcl | 12 | $16,730 |
| EliquisApixaban | 14 | $12,204 |
| XareltoRivaroxaban | 16 | $11,459 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $10,334 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,246 |
| Icosapent Ethyl | 12 | $6,240 |
| Atorvastatin Calcium | 380 | $4,640 |
| VascepaIcosapent Ethyl | 12 | $4,355 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,627 |
| Omeprazole | 120 | $2,618 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 104 | $2,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $369 | $95,14087 claims |
| Lilly USA, LLCMounjaro, Trulicity | $109 | $76,54362 claims |
| AbbVieLinzess, Vraylar, Synthroid | $598 | $42,34559 claims |
| GSKAnoro Ellipta, Breo Ellipta | $108 | $18,58135 claims |
| PfizerEliquis | $295 | $12,20414 claims |
| Johnson & JohnsonXarelto | $15 | $11,45916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Mobile
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Anthony NguyenMobile$20K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.